Mazindol

Mazindol

Mazindol (MZD) is a norepinephrine reuptake inhibitor previously approved by the FDA for the treatment of obesity, with 10 studies supporting the safety and efficacy of MZD 1 mg to 3 mg. Since the CNS noradrenergic and dopaminergic systems appear to be dysfunctional in ADHD and an open-label trial of mazindol demonstrated efficacy in improving the symptoms of pediatrics with ADHD, NLS seeks to confirm the efficacy, tolerability and safety of mazindol C.R. in the treatment of DSM-V Attention Deficit Disorder in adults and pediatrics.